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1. Introduction:
Use of point‐of‐care glucose meters for glucose monitoring is now standard of
3. Methods:
We used the internal QC material supplied by
care in the majority of hospitals. In intensive care units (ICU), handheld meters
are alternatively employed with blood gas analyzers for glucose testing and
monitoring.
Due to conflicting results in studies aimed to evaluate the benefits of intensive
insulin therapy in critically ill patients, the use of glucose meters for tight
glycemic control (TGC, i.e. insulin therapy aiming to maintain blood glucose
levels between 80 and 110 mg/dL) is matter of debate since several years.
A reason for the discrepant results may be the weak accuracy of meters used
f h d d h l l h l b l f h
Siemens with the Rapidlab 865. The three
levels of the QC were simultaneously assessed
with two AccuChek Inform II meters and one
Rapidlab 865 analyzer in triplicate on six
different days.
For each QC level, the mean of the results
obtained with the Rapidlab 865 was used as
target value for the evaluation of the Inform II
accuracy The method was validated followingin some o t e stu ies. In or er to ac ieve g ucose contro , t e re ia i ity o t e
POC glucose measurement is essential.
2. Aims:
The AccuChek Inform II meter is the new generation of Roche’s portable device
designed for use in hospitals.
As part of its analytical validation in our institution, we realized an original
comparison between the glucose meter and the blood gas analyzer Siemens
.
an approach using accuracy profiles based on
β‐expectation tolerance intervals for the total
error measurement.
Beta‐expectation tolerance intervals are intervals that
contain a proportion β of the individual values of the
population under investigation. These intervals allow the
description of the entire population. If β=0.95, this means
that 95% of the future individual values (results) of the
population will be included in the interval.
Th li i h b 10%
Rapidlab 865.
The goal was to evaluate the analytical performance of the AccuChek Inform II
and to assess whether the results obtained with this meter were comparable
with those given by the Rapidlab 865 glucose electrode.
e acceptance m ts ave een set at ±
total error. The e.noval software (Arlenda,
Liège, Be) was used to compute the results.
4. Results:
The mean glucose concentrations of the three‐levelled QC measured with the
Rapidlab 865 were 50.3, 100.5 and 208.9 mg/dL.
The accuracy profile built with the predictive tolerance interval method shows that,
on average, 95% of the future results obtained with the Inform II meters will be
transposable to those that would be obtained with the gas analyzer in the 50.3‐202.9
mg/dL (2.78‐11.1 mmol/L) range, with a ±10% error margin tolerated (Fig. 1).
Mean target  Beta‐expectation tolerance  Relative Beta‐expectation 
Risk1 (%)
Table 1. Method accuracy Fig 1. Accuracy profile. The plain line is the relativebias, the dashed lines are the β‐expectation
tolerance limits and the dotted lines represent the
t li it Th d t t th l ti
5. Discussion:
Several difficulties make target of TGC laborious to reach in critically ill patients, including the reliability of measurements with glucose
t d th i t bilit ith lt bt i d b th th d
concentration (mg/dL) limits (mg/dL) tolerance limits (%)
50.28 [ 45.38 , 48.78] [‐9.740 , ‐2.975] 1.785
100.5 [ 92.01 , 102.0] [‐8.452 , 1.486] 0.5822
208.9 [ 208.6 , 230.9] [ ‐0.1588 , 10.51] 3.727
1 Risk of having measurements falling outside of the acceptance limits.
accep ance m s. e o s represen e re a ve
error of the back‐calculated concentrations and are
plotted with respect to their targeted
concentration. The highest concentration beyond
which the β‐expectation limits go outside the
acceptance limits is 202.9 mg/dL.
me ers an e r commu a y w resu s o a ne y o er me o s.
In this preliminary work, the new AccuChek Inform II showed comparable analytical performances with the Rapidlab 865 for the
analysis of QC material. We are currently repeating the same experiments in different conditions (other instruments, lot of strips,
operators, different QC materials…) in order to confirm these results. Although a validation with patient samples remains mandatory,
our approach allowed us to compare both apparatus without any other source of variation (sample type, hematocrit, pO2…).
We think it is important to evaluate the analytical performance of an instrument before to start a large clinical study. Further
investigations are now needed to estimate the efficiency of the Inform II in TGC protocols.
